Shares of Replimune Group, Inc. (REPL) have gained 2.7% over the past four weeks to close the last trading session at $7.16, but there could still be a solid upside left in the stock if short-term ...
Shares of Replimune Group, Inc. (REPL) have gained 0.7% over the past four weeks to close the last trading session at $7.76, but there could still be a solid upside left in the stock if short-term ...
AI on the JVM accelerates: New frameworks like Embabel, Koog, Spring AI, and LangChain4j drive rapid adoption of AI-native and AI-assisted development in Java. Java 25 anchors a modern baseline: The ...
Get started with Java streams, including how to create streams from Java collections, the mechanics of a stream pipeline, examples of functional programming with Java streams, and more. You can think ...
Following a ~39% drop in the previous session, Replimune (NASDAQ:REPL) shares continued to trade lower on Friday as J.P. Morgan downgraded the stock to Underweight from Neutral, citing further ...
On Monday, Replimune Group Inc. (NASDAQ:REPL) is reeling after the FDA unexpectedly rejected its skin cancer treatment, triggering a stock plunge and a wave of investor outrage. Shares fell sharply ...
Replimune (NASDAQ:REPL) climbed more than 100% on Wednesday as Cantor Fitzgerald upgraded the cancer drug developer, citing a potential reversal of an FDA decision that rejected its lead drug ...
Recent discussions on X about Replimune Group Inc. (REPL) have been ignited by the U.S. FDA's rejection of the company's lead drug, RP1, for melanoma treatment in combination therapy. Many users are ...
NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results